DrugPatentWatch Database Preview

BRIDION Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Bridion, and when can generic versions of Bridion launch?

Bridion is a drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-six patent family members in thirty countries.

The generic ingredient in BRIDION is sugammadex sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Bridion

Bridion was eligible for patent challenges on December 15, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 27, 2021. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BRIDION

International Patents:	56
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	13
Clinical Trials:	46
Patent Applications:	1
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for BRIDION
DailyMed Link:	BRIDION at DailyMed

See drug prices for BRIDION

Generic Entry Opportunity Date for BRIDION

NDA:

022225

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRIDION

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of South Florida	Phase 3
Guangzhou General Hospital of Guangzhou Military Command	Phase 4
Yonsei University	N/A

See all BRIDION clinical trials

Pharmacology for BRIDION

Synonyms for BRIDION

1202253-72-2

343306-71-8

343306-79-6

361LPM2T56

862667-16-1

AC-30384

Bridion (TN)

CHEBI:90952

CHEBI:90953

D05940

DB06206

ERJ6X2MXV7

EX-A2600

gamma-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-octathio-, octasodium salt

MK-8616

Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-S-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-D-octaglucopyranoside

Org 25969

ORG-25969

SCH-900616

SCHEMBL13917069

Sugammadex

Sugammadex [USAN:INN:BAN]

Sugammadex Sodium

Sugammadex sodium (JAN/USAN)

Sugammadex sodium [USAN:JAN]

UNII-361LPM2T56

UNII-ERJ6X2MXV7

Paragraph IV (Patent) Challenges for BRIDION

Tradename	Dosage	Ingredient	NDA	Submissiondate
BRIDION	SOLUTION;INTRAVENOUS	sugammadex sodium	022225	2019-12-16

US Patents and Regulatory Information for BRIDION

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015		RX	Yes	No			Y	Y
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015		RX	Yes	Yes			Y	Y
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015		RX	Yes	No
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015		RX	Yes	Yes
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015		RX	Yes	No
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015		RX	Yes	No
Organon Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015		RX	Yes	Yes

International Patents for BRIDION

Country	Patent Number	Estimated Expiration
Mexico	PA02004940
Japan	3880041
Australia	7508900
Canada	2390463
China	1241576
New Zealand	518752
Canada	2380920

Supplementary Protection Certificates for BRIDION

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1259550	SPC/GB08/057	United Kingdom		PRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725
1259550	08C0052	France		PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1259550	SPC031/2008	Ireland		SPC031/2008: 20090428, EXPIRES: 20230724
1259550	SZ 47/2008	Austria		PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRÄGLICHES SALZ HIERVON
1259550	122008000068	Germany		PRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1259550	300356	Netherlands
1259550	C01259550/01	Switzerland		FUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL